TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity

TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity

Abstract In situ vaccination (ISV) triggers antitumor immune responses using the patient’s own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7/8/9 agonist formulation (CR108), in which C...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuting Wu, Rong Xiang, Yiwei Zhong, Shushu Zhao, Zhiyu Zhang, Zhihua Kou, Shijie Zhang, Yi Zhao, Cheng Zu, Gan Zhao, Yanling Xiao, Sulin Ren, Xiaoming Gao, Bin Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-01055-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41541-024-01055-z

Similar Items